Importance Understanding molecular mechanisms of response and resistance to anticancer
therapies requires prospective patient follow-up and clinical and functional validation of both
common and low-frequency mutations. We describe a whole-exome sequencing (WES)
precision medicine trial focused on patients with advanced cancer. Objective To understand
how WES data affect therapeutic decision making in patients with advanced cancer and to
identify novel biomarkers of response. Design, Setting, and Patients Patients with metastatic …